Another effort to make a long-lasting FGF21 mimetic resulted in PF-05231023 (Pfizer), which is in phase 1 clinical trial in obese patients with T2D, showing less improvement of dyslipidemia and lower body weight, but again did not lead to glucose lowering (31, 125). This evidence concerns the gene FGF21 and type 2 diabetes mellitus.